| Name | BioPharma Credit |
|---|---|
| Epic | BPCR |
| Isin | GB00BDGKMY29 |
| Index | UK250 UK350 |
| Industry |
| Latest share price | $0.90 | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | $1,013.96 | Debt ratio | n/a |
| Shares in issue | 1,129.13 | Debt-to-equity ratio | n/a |
| P/E ratio | 8.8 | Assets / equity ratio | n/a |
| Total dividends per share | 6.75¢ | Price to book value | n/a |
| Dividend yield | 7.9 | ROCE | |
| Dividend cover | 1.43 | EPS growth | |
| Earning per share | 10 | 52-week high / low | $0.80 / $0.93 |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| Special | 2025-09-25 | 2025-10-31 | 1.50¢ |
| 3rd Interim | 2025-09-25 | 2025-10-31 | 1.75¢ |
| 2nd Interim | 2025-06-26 | 2025-07-31 | 1.75¢ |
| 1st Interim | 2025-04-03 | 2025-05-07 | 1.75¢ |
| Special | 2025-01-30 | 2025-02-28 | 1.14231¢ |
| 4th Interim | 2025-01-30 | 2025-02-28 | 1.75¢ |
| 3rd Interim | 2024-09-26 | 2024-10-29 | 1.75¢ |
| 2nd Interim | 2024-07-04 | 2024-07-31 | 1.75¢ |
| 1st Interim | 2024-03-28 | 2024-04-30 | 1.75¢ |
| Company name | BioPharma Credit |
|---|---|
| Address | 51 New North Road, Exeter, United Kingdom, EX4 4EP |
| Telephone | +44 (0)1392 477500 |
| Website | http://www.bpcruk.com |
| Director | Position |
|---|---|
| Mr Harry Abraham Hyman | Chairman |
| Ms Sapna Shah | Non-Executive Director |
| Mr Duncan W A Budge | Senior Independent Director |
| Mr Rolf Soderstrom | Independent Non-Executive Director |
| Ms Stephanie Léouzon | Independent Non-Executive Director |
| Mr Colin Bond | Independent Non-Executive Director |
| Assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/12/24 | 31/12/23 | 31/12/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | |||
| Total non-current assets | |||
| Inventory / work in progress | |||
| Trade and other receivables | |||
| Cash and equivalents | 5.62 | 135.05 | 120.53 |
| Other current assets and asset held for resale | |||
| Total of all assets | 1199.62 | 1356.73 | 1364.02 |
| Liabilities $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | |||
| Long term liabilities | |||
| Other liabilites / pension etc | |||
| Total of all liabilities | 17.94 | 15.87 | 26.56 |
| Net assets $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 1181.68 | 1340.86 | 1337.45 |
| Equity $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | |||
| Minority interests | n/a | n/a | n/a |
| Retained earnings | |||
| Share premium account | 607.12 | 607.12 | 607.12 |
| Total equity |
| Income $ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | 148.63 | 155.36 | 212.22 |
| Operating profit | 122.27 | 132.4 | 176.39 |
| Pre-tax profit | 122.27 | 132.4 | 176.39 |